Business Wire

Amylyx Pharmaceuticals Provides Global Regulatory Update on AMX0035 for ALS

Share

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of ALS. The company intends to submit a Marketing Authorization Application (MAA) for AMX0035 to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) by the end of 2021. As previously reported, the company plans to submit a marketing application with Health Canada Q2 2021.

The FDA has expressed an interest in seeing data from an additional placebo-controlled clinical trial prior to receiving a New Drug Application (NDA), the vehicle through which a pharmaceutical sponsor formally proposes that the FDA approve an investigational product. To fulfill the FDA’s request and to continue to build upon the growing body of evidence supporting AMX0035 for the potential treatment of ALS, Amylyx plans to initiate a Phase 3 clinical trial in Europe and the United States. The trial is expected to begin enrollment in Q3 2021. The FDA also expressed that it would continue to discuss with Amylyx how regulatory requirements may be met in the most expeditious way possible.

Amylyx is also continuing to discuss AMX0035 with additional regulatory bodies worldwide to determine the most appropriate path forward.

“People living with ALS need clinical answers and solutions quickly. We have been in close contact with physicians and global health authorities to rapidly evaluate AMX0035 for the treatment of ALS,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “We are thrilled to plan our submissions in Europe and Canada and will continue working closely with regulators and the ALS community worldwide to determine the most expeditious and responsible pathways to advance AMX0035 through the clinical development process. We appreciate all of the advice and guidance from the regulators worldwide and will continue to act with haste and to keep the community updated.”

CENTAUR was a 24-week placebo-controlled study of 137 participants with ALS that evaluated the safety and efficacy of AMX0035. The trial was led by investigators at the Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with the Northeast ALS Consortium. As published in the New England Journal of Medicine (NEJM), the study met its primary efficacy endpoint of slowing ALS progression as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). The rates of adverse events were similar between the AMX0035 and placebo arms of the study. However, discontinuations related to adverse events occurred more frequently in the AMX0035 arm than in the placebo arm.

Participants who completed CENTAUR were eligible to enroll in an open-label extension (OLE) and receive AMX0035. In a nearly three-year overall survival analysis of all randomized participants from CENTAUR that was published in Muscle & Nerve, those originally randomized to AMX0035 had a 44% lower risk of death compared to those originally randomized to placebo.

“With the results from CENTAUR, we showed that AMX0035 may provide people living with ALS hope and the chance to function better and live longer lives,” said Sabrina Paganoni, M.D., Ph.D., principal investigator of the CENTAUR trial, investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital and Assistant Professor of PM&R at Harvard Medical School and Spaulding Rehabilitation Hospital. “We are very excited to see AMX0035 advancing on multiple regulatory fronts and remain optimistic that it can potentially help people living with ALS around the world.”

“ALS is a devastating progressive disease that impacts patients and their families not only physically, but also mentally and emotionally,” said Leonard H. van den Berg, M.D., Ph.D., Professor of Neurology at UMC Utrecht in the Netherlands and Chairman of the Treatment Research Initiative to Cure ALS (TRICALS), a large European trial network dedicated to finding a treatment for ALS. “After decades of ALS trial failures, AMX0035 has given us the hope that a new potential treatment option may be on the horizon for those living with ALS. We remain highly encouraged as AMX0035 continues to move through the regulatory review process, and are excited for the Phase 3 clinical trial.”

“The pivotal Phase 3 clinical trial will catalyze a global collaboration between Amylyx, European and US ALS experts, advocacy groups, and clinical trial networks,” said Merit Cudkowicz, MD, co-principal investigator of the CENTAUR trial and co-founder of the Northeast ALS Consortium, Director of the Healey & AMG Center for ALS and Chair of Neurology at Massachusetts General Hospital and the Julieanne Dorn Professor of Neurology at Harvard Medical School. “We hope this is just the beginning of providing new options to people living with ALS.”

“People with ALS are fighting against this disease every day,” said Evy Reviers, Chairwoman of European Organization for Professionals and Patients with ALS (EUpALS) and CEO of ALS Liga Belgium. “As a caregiver of a loved one with ALS, I know how critical it is to make potential treatment options available to the ALS community. On behalf of EUpALS, I look forward to working with industry, academia and health authorities to make that a reality.”

“We are pleased to share our plans to initiate regulatory filing in Europe,” said Justin Klee, Co-CEO and Co-Founder of Amylyx. “Every single day matters for people living with ALS and we will continue to work with the U.S. FDA and global regulatory agencies to meet their requests so that we can advance AMX0035 through the clinical development process as quickly as possible. We will share updates on our progress with the community as we have them.”

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.

Contact information

Merissa Muller
Finn Partners
(617) 778-6633
Merissa.Muller@finnpartners.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Declares Dividend for Second Quarter 20215.5.2021 22:15:00 CEST | Press release

IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.77 per share of its common stock, payable on July 6, 2021 to shareholders of record as of June 25, 2021. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20210505006076/en/Contact information Michael DeVeau Chief Investor Relations & Communications Officer 212.708.7164 Mich

Zynga Announces First Quarter 2021 Financial Results5.5.2021 22:05:00 CEST | Press release

Zynga Inc. (Nasdaq: ZNGA) today released financial results for its first quarter ended March 31, 2021 by posting management’s Q1 2021 Quarterly Earnings Letter to its Investor Relations website. Please see the attached Quarterly Earnings Letter or visit http://investor.zynga.com/financial-information/quarterly-results to access the letter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005238/en/ “We are off to an excellent start in 2021 with record Q1 results driven by breakout performances from our live services, new games and hyper-casual portfolio,” said Frank Gibeau, Chief Executive Officer at Zynga. “Today, we announced our intent to acquire Chartboost, a leading advertising and monetization platform. This transformational acquisition will combine Zynga’s high-quality games portfolio and first-party data with Chartboost’s proven advertising and monetization platform to create a new level of audience scale and mea

Zynga Enters Agreement to Acquire Chartboost5.5.2021 22:05:00 CEST | Press release

Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, today announced it has entered into a definitive agreement to acquire Chartboost, a leading mobile programmatic advertising and monetization platform. Along with its talented team, Chartboost brings a global audience of more than 700 million monthly users and more than 90 billion monthly advertising auctions. Together, Zynga and Chartboost possess all the elements of a complete, next generation platform: high-quality content, direct player relationships, massive reach and full-stack advertising technology that can be applied across Zynga’s game portfolio and Chartboost’s advertising partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005033/en/ Zynga Enters Agreement to Acquire Chartboost Chartboost is a unified advertising platform that includes a Demand Side Platform (DSP) as well as Supply Side Platform (SSP) and mediation capabilities del

Altasciences Acquires Calvert Laboratories5.5.2021 18:59:00 CEST | Press release

Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories, a preclinical CRO located on the U.S.A.’s East Coast. This acquisition will complement Altasciences’ current preclinical West Coast operations, located just north of Seattle, WA. For more than 40 years, Calvert Laboratories has been working with clients to help develop the next generation of therapeutics aimed at extending and improving human life; in line with Altasciences’ focus on getting better drugs to the people who need them faster. “This acquisition will increase small molecule expertise as well as add efficacy pharmacology, ophthalmology, and carcinogenicity study capabilities, to Altasciences’ current preclinical offering. Furthermore, it expands Altasciences’ presence on the East Coast, and the site is conveniently located in close p

RMS Global Catastrophe Model Leader Launches First Climate Change Models, Enabling New Risk Insights5.5.2021 17:14:00 CEST | Press release

RMS, the world’s leading catastrophe risk modeling and solutions company, revealed that according to its new Climate Change Models, and based on today’s exposures, insured average annual losses (AAL) from North Atlantic Hurricane wind could increase by as much as 24 percent by 2050*, and European Flood risk AAL could increase by up to 59 percent by 2050**, based on no mitigating factors taken. The new RMS Climate Change Models combine the RMS financial impact modeling framework with the best climate science consensus, including from the Intergovernmental Panel on Climate Change (IPCC). Generally available in June 2021, these models provide the most comprehensive climate change insights for North Atlantic Hurricane, Europe Inland Flood, and Europe Windstorm. Each model quantifies and differentiates the impacts of acute physical risk due to variable potential climate change scenarios (known as Representative Concentration Pathways or RCPs), different time horizons, and within specific re

Nel ASA: Receives Purchase Order for 2 MW PEM Electrolyser5.5.2021 16:46:00 CEST | Press release

Nel Hydrogen Electrolyser, a division of Nel ASA (Nel, OSE:NEL), received a purchase order for a 2 MW, fully containerized MC400 electrolyser from H2 Energy. "This is a new milestone achieved in the development of a commercial green hydrogen infrastructure, clearly showing that hydrogen for heavy duty vehicles is a reality today. We are proud that our compact PEM containerized solution has been selected for this second site to supply the refueling stations network," says Raymond Schmid, VP Sales and Marketing EMEA, Nel Hydrogen Electrolyser. The 2 MW PEM electrolyser is the second system to be delivered as part of the green hydrogen infrastructure network that is currently supplying hydrogen to the first 46 Hyundai trucks already operating in Switzerland and aiming to reach a fleet of 1,600 by 2025. The system will be filling 350 barg trailers directly at site to dispatch the hydrogen to the Hydrospider network in Switzerland. H2 Energy is working together with various partners to esta

Sevan Multi-Site Solutions Celebrates 10 Years5.5.2021 15:00:00 CEST | Press release

Sevan Multi-Site Solutions, Inc. (Sevan)—a global leader in innovative design, program management, construction services and data analytics—is excited to celebrate its 10th anniversary. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005438/en/ Sevan Multi-Site Solutions celebrates its 10th Anniversary. (Graphic: Business Wire) For a decade, Sevan has committed to providing multi-site solutions for dozens of clients along entire project life cycles. Sevan stays true to the values and core principles it was founded on: Integrity, Respect, Teamwork, Excellence and Charity. Since its inception, Sevan’s entrepreneurial spirit has been accompanied by a culture that is innovative, respectful, inclusive and progressive. “What a joy it has been to work with marvelous people over the last decade while we grew our business,” Jim Evans, President and CEO said. “Thanks so much to our clients, business partners and Sevan team member

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom